辉瑞的跑路来得猝不及防。日前,辉瑞宣布,每日一次的小分子GLP-1药物Danuglipron两项1期剂量优化研究达到了关键的药代动力学目标,并确认了可以在3期提供有竞争力的疗效和耐受性的配方和剂量。然而,这些试验数据的公布,却结束了Danuglipron的生命。辉瑞决定取消Danuglipron的研发,核心原因在于,有1名患者可能受到药物诱导的肝损伤。从结果来看,辉瑞的决定未免有些着急。毕竟,该...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.